[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase of 4,150,000 ordinary shares of £0.01 each on 19 September 2025 under the second tranche of its share buyback programme announced 31 July 2025. The shares were purchased on the London Stock Exchange and CBOE (UK)/CXE across the session; a full breakdown of individual trades is provided via the Company link. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 23,037,545 are treasury shares, leaving 8,929,316,103 voting shares.

Positive

• Repurchase executed: Company bought 4,150,000 ordinary shares under the announced buyback programme.
• Treasury treatment: The Company intends to hold the purchased shares as treasury shares, as stated in the filing.
• Regulatory disclosure provided: Full trade breakdown link included for market verification and transparency.

Negative

• None.

Insights

Financial Analyst

TL;DR: Haleon executed a tranche buyback of 4.15 million shares and will hold them as treasury stock; share count for voting has been updated.

This disclosure is a routine, transparent update on the company's ongoing repurchase programme. It confirms the second tranche execution and provides post-settlement share counts that matter for shareholder notification thresholds. The announcement includes a link to a full trade breakdown, allowing market participants to verify timing and execution. There are no earnings, debt or liquidity figures disclosed here to assess the buyback's funding or relative size.

Corporate Governance Expert

TL;DR: The company recorded treasury purchases and refreshed its public voting share total for regulatory disclosure purposes.

The filing fulfills regulatory obligations by reporting the aggregate number of shares repurchased and the updated number of voting shares, which shareholders use to determine notification requirements under disclosure rules. The intended treatment of the repurchased shares as treasury shares is explicitly stated. No changes to board composition, shareholder rights, or capital structure mechanics beyond the share counts are described in this notice.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	22 September 2025 - Transaction in Own Shares

99.1

Haleon plc: Transaction in own shares

22 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 4,150,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	19 September 2025	19 September 2025	19 September 2025
Number of Shares purchased:	3,507,000	-	643,000
Highest price paid per Share (p):	342.3000	-	341.0000
Lowest price paid per Share (p):	338.8000	-	338.8000
Volume weighted average price paid per Share (p):	340.7178	-	340.1845

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 23,037,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,929,316,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/1366A_1-2025-9-19.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 22, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLNCF) announce in this Form 6-K?

Haleon announced the purchase of 4,150,000 ordinary shares under the second tranche of its buyback programme and that the shares will be held as treasury shares.

How many voting shares does Haleon have after the repurchase?

After settlement the number of ordinary shares with voting rights is 8,929,316,103.

How many shares does Haleon hold as treasury shares now?

The Company holds 23,037,545 shares as treasury shares following this repurchase.

Where were the shares purchased?

The filing states purchases occurred on the London Stock Exchange and CBOE (UK)/CXE on 19 September 2025; a full trade breakdown link is provided.

Does the announcement include financial details on how the buyback was funded?

No. The filing does not disclose funding sources, cash impact, or effect on earnings per share.